Shares of Absci Corporation (NASDAQ:ABSI) rallied 24% on Wednesday after the company released interim safety data from the Phase 1 program for ABS-201, its investigational antibody aimed at treating hair loss.
The single ascending dose portion of the study enrolled 32 healthy adult volunteers divided across four blinded dose cohorts. Doses ranged from 150 mg to 1,800 mg and were administered intravenously. According to Absci, investigators observed favorable safety outcomes across all cohorts and reported no serious adverse events.
Most treatment-emergent adverse events were characterized as mild. The company noted a single instance of a moderate headache in the third cohort; that event was assessed by the study team as unlikely to be related to the investigational product.
ABS-201 is an anti-prolactin receptor antibody developed to address androgenetic alopecia, a condition the company estimates affects roughly 80 million Americans. Absci said the antibody demonstrated an estimated half-life of at least 65 days, a pharmacokinetic profile the company said could support administration of two or three injections over a six-month period.
Following the single ascending dose evaluation, Absci has initiated the first multiple ascending dose cohort in participants who have androgenetic alopecia. The company provided a development timeline that includes interim proof-of-concept data targeted for the second half of 2026 and full proof-of-concept results expected in early 2027.
Financing and use of proceeds
Separately from the clinical update, Absci announced an underwritten offering of 13.5 million shares priced at $7.41 each, expected to generate approximately $100 million in gross proceeds before fees. The financing includes participation from Eli Lilly & Company as well as institutional investors Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile and another large investment management firm.
Absci said it intends to allocate the proceeds to advance ABS-201 across programs in androgenetic alopecia and endometriosis, to support a planned Phase 2 trial in endometriosis later this year, and for general corporate purposes.
What the update means
The interim Phase 1 safety readout and the long estimated half-life are material pieces of early clinical data for ABS-201, and the company has moved into multiple ascending dose testing in affected patients. The priced equity offering is expected to provide capital to fund next-stage studies in two therapeutic areas.
Absci's stated timeline places interim proof-of-concept readouts in the latter half of 2026 and full proof-of-concept data in early 2027 for the androgenetic alopecia program.
Key points
- ABS-201 Phase 1 single ascending dose data in 32 healthy adults showed favorable tolerability and no serious adverse events across four IV dose cohorts (150 mg to 1,800 mg).
- The antibody demonstrated an estimated half-life of at least 65 days, consistent with potential dosing of two to three injections over six months; multiple ascending dose testing in patients has begun.
- Absci priced a 13.5 million-share offering at $7.41 per share to raise roughly $100 million before fees, with participation from Eli Lilly & Company and several institutional investors to fund programs in androgenetic alopecia and endometriosis.
Risks and uncertainties
- These are interim Phase 1 safety results from a small sample of healthy volunteers - further data from multiple ascending dose cohorts and proof-of-concept studies are required to establish efficacy and longer-term safety, affecting biotech and pharmaceutical markets.
- The planned use of proceeds includes funding additional clinical trials; execution risks or changes in trial timelines could affect Absci's development program and capital needs, with implications for the company and healthcare investors.
- Participation by institutional investors and a strategic partner does not guarantee clinical success; outcomes from upcoming trials will determine future value and market reaction.
Bottom line
Absci's interim Phase 1 safety data for ABS-201 and the subsequent capital raise represent early but meaningful steps in advancing the program toward patient testing and proof-of-concept milestones slated for 2026 and 2027. Investors and market participants will be watching subsequent multiple dose data and the planned Phase 2 endometriosis trial later this year.